Dec 12,2017

Berkshire NHS Foundation Trust offers cutting edge diabetes support

Changing Health, the service transforming digital education and support for people with Type 2 diabetes, is now available for almost a quarter of a million people with diabetes to rapidly improve their health outcomes. A new partnership between Berkshire Healthcare NHS Foundation Trust and Changing Health means the service is now operating in 16 NHS organisations across the UK, together covering 8% of the Type 2 diabetes population – a total 241,675 people. ​

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 13,2017

Arkessa, Brighter, Ericsson and Gemalto partner to provide global connectivity solutions for Actiste.

Brighter AB have selected the Arkessa eUICC solutions to support the global market launch of Actiste, a mobile health solution that simplifies insulin-treated diabetes by gathering and sharing personal health data between patient and healthcare professionals through a connected pocket-sized device.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Dec 14,2017

Brighter draws down the fourth tranche under the financing agreement with L1 Capital and issues additional free warrants to its shareholders

Brighter has called upon a fourth Tranche of SEK 10 million in line with the terms from the financing agreement communicated on the 26thof April 2017. The transaction is carried out through a private placement of convertible notes with warrants attached.

View Analyst & Ambassador Comments
Go to original news
Dec 14,2017

Tandem Diabetes Care Announces Issuance of Patent Related to Automated Insulin Delivery Technology

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.S. Patent No. 9,833,177 titled "Insulin Pump Based Expert System." This patent is part of the portfolio of intellectual property acquired by the Company from Smiths Medical ASD, Inc. in 2013. It refers to a pump system that suspends, among other operations, the delivery of insulin if a user's sensor glucose data reaches or falls below an acceptable level, alerts the user and recommends that the user initiate a blood glucose measurement.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Dec 14,2017

Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial

The objective of this randomized controlled trial is to implement and evaluate the feasibility, cost-effectiveness, and sustainability of a reality television–based lifestyle intervention program. This intervention program is delivered via a mobile phone app (mDiab) to approximately 1500 Android smartphone users who are adults at a high risk for type 2 diabetes from three cities in India, namely, Chennai, Bengaluru, and New Delhi.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 18,2017

DarioHealth Gains Regulatory Approval in Australia for iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter

DarioHealth Corp. (Nasdaq: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it received the Therapeutic Goods Administration (TGA) Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System in Australia. The regulatory approval ensures that consumers in the Australian market will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8 and iPhone X.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Dec 20,2017

Insulet Corporation to Present at Upcoming Investor Conference

Insulet Corporation (NASDAQ: PODD) (Insulet), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2018, at 4:30pm (Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 21,2017

Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results

Nemaura Medical Inc. (“Nemaura”) (OTCQB: NMRD), a medical technology company developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes, today announced the completion of its sugarBEAT® European clinical trial programme and positive interim accuracy data.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 21,2017

Brighter showcases complete Actiste in new video

Brighter’s Actiste® is a unique service that simplifies everyday life for diabetics and stimulates behavioral change. By combining personal and aggregated data the service enables better healthcare. Diabetes is one of today's most costly diseases and the number of sufferers is growing all over the world, Sweden included.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 27,2017

DarioHealth Granted Another U.S. Patent Strengthening its Core Technology

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the U.S. Patent and Trademark Office has issued the Company patent #9832301 titled "Systems and Methods for Adjusting Power Levels on a Monitoring Device."

PRODUCT

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES